{"chunk":"CENTER FOR DRUG EVALUATION AND RESEARCH\nDistributed Manufacturing of Drugs:\nStakeholder Feedback and Action Plan\nNovember 2023\nDisclaimer: This paper is for discussion purposes only of stakeholder feedback and is not\na draft or final guidance. As such, this document is not intended to convey any current or\nfuture requirements, recommendations, or p","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ecommendations, or policy related to distributed manufacturing.\nExecutive Summary\nFDA\u2019s Center for Drug Evaluation and Research (CDER) established the\nFramework for Regulatory Advanced Manufacturing Evaluation (FRAME)\ninitiative to foster a regulatory framework to support the adoption of advanced\nmanufacturing technologies that could benefit patien","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"could benefit patients. FRAME prioritized\ndistributed manufacturing (DM) and point-of-care manufacturing (POC) as\ntwo related technologies that have the potential to advance pharmaceutical\nmanufacturing. The discussion paper Distributed Manufacturing and Point-of-Care\nManufacturing of Drugs published on October 14, 2022 (October 2022 discussion\npap","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" 2022 discussion\npaper),1 and the public workshop The Regulatory Framework for Distributed\nand Point-of-Care Pharmaceutical Manufacturing: An Opportunity for DM\/POC\nStakeholder Engagement was held from November 14 to 16, 2022.2 To ensure that\nFDA\u2019s evaluation of the regulatory framework for these technologies is thorough,\nstakeholders were invited ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"olders were invited to comment on the discussion paper and provide\nfeedback through moderated discussions at the public workshop.\nThis paper summarizes stakeholder feedback in areas such as terminology,\noperating models, central and host sites, approaches for meeting product\nspecifications, comparisons to other regulated products, and international","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"s, and international\nharmonization. Stakeholders generally:\n\u2022\nIdentified areas in which they seek additional regulatory clarity regarding DM\ntechnologies for drugs and biological products3\n\u2022\nSeek assurance that regulations and policies are compatible with DM strategies\nfor drugs and biological products\n\u2022\nSeek clarified regulatory expectations to fa","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"y expectations to facilitate the implementation of DM for\ndrugs and biological products\n\u2022\nSeek international harmonization on the regulation of DM technologies to\nfacilitate the adoption of DM for drugs and biological products\n1\n2\n3\nFor the discussion paper available on CDER\u2019s FRAME initiative website at https:\/\/www.fda.gov\/media\/162157\/\ndownload?a","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"a\/162157\/\ndownload?attachment, comments were submitted to https:\/\/www.regulations.gov, Docket No. FDA-2022-N-2316.\nSee CDER\u2019s FRAME workshop website available at https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdapqri-\nworkshop-regulatory-framework-distributed-and-point-care-pharmaceutical-manufacturing.\nAll references to drugs include both human","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"s include both human drugs and biological products (including those regulated by CBER), unless\notherwise specified.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n2\nIn addition to summarizing stakeholder feedback, this paper describes CDER\u2019s\nactions to date and its action plan for the DM regulatory framework in alignment\nw","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ework in alignment\nwith the four FRAME priorities:\n1. Seek and analyze input\na) Receive input from stakeholders in response to the discussion paper and at\nthe public workshop (complete)\nb) Engage participants in the CDER Emerging Technology Program (ETP) and\nthe Center for Biologics and Research (CBER) Advanced Technologies\nTeam Program (CATT)\nc) I","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" Program (CATT)\nc) Incorporate stakeholder feedback to address risks and clarify regulatory\nexpectations (priorities 2 and 3 below)\n2. Address risks to ensure that regulations and policy are compatible with future\nadvanced manufacturing technologies\na) Conduct a comprehensive analysis of regulatory requirements applicable to\nDM strategies\nb) Assess","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"strategies\nb) Assess the ability of FDA\u2019s IT systems to receive and store location\ninformation and inform inspections\n3. Clarify expectations for stakeholders implementing advanced manufacturing\na) Develop guidance, as appropriate, to clarify areas of regulatory uncertainty\n(three proposed draft guidances in development)4\nb) Evaluate existing polic","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"luate existing policy to enable adoption of suitable DM technologies\n4. Harmonize regulatory approaches\na) Publish internationally harmonized guidance for industry Q13 Continuous\nManufacturing of Drug Substances and Drug Products (March 2023),5 as\nmany DM units may use continuous manufacturing (complete )\nb) Coordinate with international regulatory","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"rnational regulatory partners to promote global adoption\nof DM technologies\n4\n5\nSee the document titled CDER Guidance Agenda, New & Revised Draft Guidance Documents Planned for Publication in\nCalendar Year 2023 (July 2023), available at https:\/\/www.fda.gov\/media\/134778\/download.\nFDA updates guidances periodically. For the most recent version of a g","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ecent version of a guidance, check the FDA guidance web page at\nhttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n3\nI. Introduction\nAdvanced manufacturing technologies have the potential to improve the reliability\nand robustness of manufacturing process","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"anufacturing processes and supply chains and increase\ntimely access to quality medicines. As advanced manufacturing technologies are\nemerging rapidly, FDA aims to foster a regulatory framework that supports the\nadoption of advanced manufacturing technologies to benefit patients, keep pace\nwith innovation, and support public health. CDER established","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"th. CDER established the Framework\nfor Regulatory Advanced Manufacturing Evaluation (FRAME) initiative to\nprovide clarity and reduce uncertainty for stakeholders aiming to use advanced\nmanufacturing technologies to produce quality drugs and biological products.6\nFRAME\u2019s goal is to identify potential regulatory areas of consideration and develop\nan ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"tion and develop\nan action plan to address the regulatory framework for advanced manufacturing\ntechnologies. FRAME\u2019s four priorities are to:\n1. Seek and analyze input to ensure that FDA\u2019s understanding of advanced\nmanufacturing technologies for drugs and biological products is thorough and\nthe analysis of the regulatory framework is science- and ri","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"k is science- and risk-based\n2. Address risks to ensure that regulations and policy are compatible with future\nadvanced manufacturing technologies\n3. Clarify expectations for stakeholders implementing advanced manufacturing\n4. Harmonize regulatory approaches to ensure that global regulatory practice is\nclear to stakeholders implementing advanced ma","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ementing advanced manufacturing\nTo address the first priority above, FDA engaged stakeholders on distributed\nmanufacturing (DM) and POC technologies in two different forums. The first was\na discussion paper Distributed Manufacturing and Point-of-Care Manufacturing of\nDrugs for public comment in the Federal Register.\n7 The discussion paper presented","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"sion paper presented\nareas of consideration and potential policy development identified by evaluating\nthe regulatory framework for DM and POC technologies. The second was a\n6\n7\nAll references to drugs include both human drugs and biological products (including those regulated by CBER), unless\notherwise specified.\nSee the document titled Discussion ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"t titled Discussion Paper: Distributed Manufacturing and Point-of-Care Manufacturing of Drugs; Request\nfor Information and Comments that published in the Federal Register of October 14, 2022 (87 FR 62416).\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n4\n3-day public workshop held with the Product Quality Research Institut","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ty Research Institute (PQRI)\non The Regulatory Framework for Distributed and Point-of-Care Pharmaceutical\nManufacturing: An Opportunity for DM\/POC Stakeholder Engagement that was\nheld from November 14 to 16, 2022.8 The public workshop included presentations\nby stakeholders developing DM and POC technologies and moderated discussion\nsessions for all","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ion\nsessions for all participants on areas such as terminology, operating models,\ncentral and host sites, the pharmaceutical quality system (PQS),9 and control\nstrategies and specifications.\nThe sections of this paper that follow: (1) summarize stakeholder feedback on\nthe DM and POC regulatory framework received through public comments on\nthe Octob","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"omments on\nthe October 2022 discussion paper and at the public workshop; and (2) provide\na description of FDA\u2019s planned actions to address the regulatory framework\nconcerning these advanced manufacturing technologies.\nII. Summary of Stakeholder Feedback\nA. Terminology\nThe October 2022 discussion paper included terminology describing DM and POC\nmanu","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"bing DM and POC\nmanufacturing, based on preliminary stakeholder engagements10 regarding these\ntechnologies.\nIn written comments and through discussion during the PQRI workshop,\nstakeholders provided the following feedback with respect to the terminology used\nin the October 2022 discussion paper. Stakeholder feedback clarified that not all\nDM units ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"at not all\nDM units are intended to be mobile (i.e., mobility may not be a defining feature of a\nDM unit).\nStakeholders noted that the term point-of-care (POC) describes a manufacturing\nlocation, rather than a manufacturing technology. For example, health care\nproviders might understand the term to mean a location where samples are\ncollected or a t","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"are\ncollected or a test is performed on a patient. Stakeholders shared that POC\nmanufacturing might not always be a subset of DM because, except for some\n8\n9\n10\nSee the FDA\/PQRI workshop agenda and materials available at https:\/\/pqri.org\/fda_pqri_poc_dm_workshop\/.\nSee the internationally harmonized guidance for industry Q10 Pharmaceutical Quality S","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"maceutical Quality System (April 2009).\nPreliminary stakeholder engagements include a 2021 report titled Innovation in Pharmaceutical Manufacturing on the\nHorizon: Technical Challenges, Regulatory Issues, and Recommendations issued by the National Academies of Sciences,\nEngineering, and Medicine, available at https:\/\/nap.nationalacademies.org\/catal","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"lacademies.org\/catalog\/26009\/innovations-in-pharmaceutical-\nmanufacturing-on-the-horizon-technical-challenges-regulatory, and include industry meetings with ETP and CATT.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n5\napplications of so-called self-contained distributed manufacturing,\n11 POC\nmanufacturing might not be in","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ring might not be intended to be part of a decentralized manufacturing\nstrategy or entail the use of DM units.\nAdditionally, stakeholders noted that POC is an existing term used differently in\nseveral medical product areas. Feedback highlighted existing products that some\nstakeholders consider to be made at POC (e.g., certain radiopharmaceuticals\nc","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"diopharmaceuticals\ncovered in 21 CFR part 211 and positron emission tomography (PET) drugs\ncovered in part 212 (21 CFR part 212)). Other products that stakeholders\nsuggested could be considered to be made at POC include human cellular and\ntissue-based products (HCT\/Ps) produced at or near a medical health care facility\n(HCF) accommodating the patie","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ommodating the patients receiving these products or certain medical\ndevices that process blood or HCT\/Ps. Stakeholders shared the concern that any\nnew elements of regulatory framework should avoid disrupting existing POC-\nrelated articles, processes, and operations.\nB. DM PQSs\nThe October 2022 discussion paper presented the following two potential ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"owing two potential PQS\napproaches for DM: (1) host sites networked and overseen by a centralized PQS,\nand (2) a unit with its own PQS (decentralized PQS).\nStakeholders supported the reasoning that a centralized PQS model is essential to\nDM for CDER-regulated products, especially to ensure regulatory compliance. (See\nalso section II.H below.) Some ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"n II.H below.) Some stakeholders suggested that centralized control over\nremote manufacturing locations could provide quality oversight by sharing real-time\ndata and documentation through a digital network across a fleet of DM units. Some\nexplained that existing tools, such as cloud-based data management systems and\ndigital connections, could be ap","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ections, could be applied to permit a centralized PQS site to oversee\nand ensure consistent drug product quality across all manufacturing locations\nunder its control. Stakeholders proposed that a designated person or designated\npeople (e.g., fleet administrators) could be responsible for managing DM units\ndeployed to different host sites. Feedback ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ost sites. Feedback suggested that information to support\nthat the centralized PQS has adequate oversight of multiple DM units across\nmultiple geographical locations could be provided in a regulatory submission and\nassessed through facility evaluation.\nStakeholders also suggested that a centralized PQS, similar to traditional\nmanufacturing location","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"nufacturing locations, might help to ensure site-to-site consistency through\noversight of starting materials, active pharmaceutical ingredients (APIs), and\ninactive ingredients for each host site. Some proposed that a centralized inventory\n11\nSelf-contained distributed manufacturing is not a term that FDA has necessarily adopted, but, for ease of r","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":", but, for ease of reference, this\npaper will use this term to refer to the subset of manufacturing that stakeholders consider to be a subset of DM.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n6\nmight distribute to host sites appropriately sourced, qualified, and released starting\nmaterials; APIs; or inactive ingredient","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" inactive ingredients. Some feedback also suggested that\nelectronic safeguards, such as kitting and barcoding, could help ensure that only\nqualified and released raw\/starting materials and validated standard operating\nprocedures (SOPs) are used with the manufacturing unit. Some explained\nthat the central site could also collect, hold, and test rete","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" hold, and test retention and stability\nsamples to control the consistency of product attributes across manufacturing\nlocations. Stakeholders also stated that deviation, corrective action, and change\nmanagement through a centralized PQS (rather than a decentralized PQS) might\nmore effectively ensure product consistency across host sites. Some opine","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"st sites. Some opined that\nspecific mechanisms may be necessary to contemporaneously manage deviations,\nfailure investigations, corrective actions, and changes across a network of host\nsites. Stakeholders did not address who, either central or local personnel, would\nneed to perform these and other quality system functions.\nStakeholders indicated th","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"holders indicated that a decentralized PQS model may not be preferable\nfor all traditional facilities that manufacture CDER-regulated product due to the\nneed for local control over raw and starting materials and product consistency. In\ncontrast, some stakeholders explained that both centralized and decentralized\nPQS models may be applicable for som","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"e applicable for some CBER-regulated products. For example,\nstarting materials for these products (e.g., autologous T cells) are patient-specific\nand may have inherent variability not applicable to CDER-regulated products; thus,\ndifferent considerations may be needed for their control.\nC. DM Applicants\nStakeholders noted that the types of DM applic","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"e types of DM applicants may differ among CBER- and\nCDER-regulated products. Stakeholders opined that an HCF might be an applicant\nand responsible for complying with CGMP requirements for CBER-regulated\nproducts, such as HCT\/Ps; however, some opined that such a model may be less\nsuited for CDER-regulated products. Stakeholders further opined that a","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"urther opined that applicants\nof CDER-regulated products could either own and operate or contract the site\ncontrolling the centralized PQS, similar to contracting a traditional brick-and-mortar\ncontract manufacturing organization.\nD. Operators\nStakeholders posited that traditional manufacturing personnel12 would likely\noperate most DM units; howeve","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ost DM units; however, some predicted that self-contained DM\nunits might be operated by either traditional manufacturing personnel or those\naffiliated with the HCF hosting the unit. Stakeholders proposed that, in some\n12\nSee 21 CFR 211.25.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n7\ncases, employees of either the appl","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"s of either the applicant or a third-party contractor might operate\nself-contained DM units. Some suggested that operators might be trained and\noverseen by the centralized PQS to be responsible for operating a unit at the\nhost site. Multiple stakeholders suggested that the operator of a self-contained\nDM unit for CDER-regulated products would be re","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"products would be responsible for ensuring that\nthe unit is used appropriately (e.g., per approved instructions for use or user\nmanuals) within validated operating conditions and used for completing appropriate\ntraining. Others suggested that the operator for CBER-regulated products might be\nexpected to perform extensive operations that include man","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ons that include manipulation of raw\nmaterials and\/or manufacturing equipment and execution of test methods. Some\nexplained that the extent of operational and quality responsibilities delegated to the\nunit operator might depend on the features of a given technology and the\ncomplexity of the product, which in some cases might require an assessment o","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"uire an assessment of\noperator performance at host sites.\nStakeholders stated that a centralized PQS and onboard technology could manage\noperator access, limiting operation to those who are appropriately qualified.\nStakeholders proposed that manufacturers might establish a standardized training\nstrategy to qualify unit operators. Some suggested tha","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":". Some suggested that such training could be\ncommunicated electronically to individual operators at host sites and\/or through\naugmented reality training. In general, stakeholders held the view that standardized\ntraining developed and maintained by the centralized PQS can contribute to\nconsistent drug product quality and process performance across a","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"performance across all manufacturing\nlocations.\nE. Establishments\nThe October 2022 discussion paper identified that considering a different\napproach for registration and listing of DM units may be needed.13 The discussion\npaper acknowledged that a DM establishment might consist of mobile DM units\nconnected or networked to a single, centralized PQS.","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"le, centralized PQS.\nAlthough stakeholders explained that manufacturers might maintain real-time\nlocation information for mobile units, which could be detected by a global\npositioning system (GPS), such an approach could potentially raise operational\nquestions. For example, some suggested that CDER\u2019s facility catalog may need\nto accommodate an FDA ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" accommodate an FDA Establishment Identifier number that is able to identify\nDM units. Stakeholders proposed various mechanisms for reporting DM unit\nlocation changes, such as supplemental applications (e.g., changes being effected\nsupplements), annual reports, and annual updates to master files. Feedback\nsuggested that any such approach would need","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" approach would need to be sufficiently timely or frequent,\n13\nThe regulations in 21 CFR 207.1 define establishment as \u201ca place of business under one management at one general\nphysical location. . . .\u201d\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n8\nbased on the mobility of the technology. Some explained that using existi","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ed that using existing\nregulatory processes for frequent updates to an application could be a significant\nburden on both the applicant and FDA.\nStakeholders stated that current regulations may not need to be modified to\naccommodate the registration and listing of stationary DM units; however, some\nexplained that manufacturers who operate mobile DM ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"o operate mobile DM units may be required\nto make multiple and\/or frequent updates to the physical address of the unit\nidentifying each change in location to facilitate inspection by FDA. Stakeholders\nproposed that manufacturers could register a central site at a fixed location and\nregister a fixed location as part of that registration and identify","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"tration and identify the mobile DM units\nunder the control of the centralized PQS. Some stakeholders noted that a similar\napproach is used to register mobile establishments for blood collection.\nF. Changing and Adding Locations of DM Units\nThe October 2022 discussion paper acknowledged that, under the existing\nframework, applicants might need to de","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"nts might need to demonstrate bioequivalence and\/or generate\nanalytical comparability data, conduct method transfer and validation, and generate\nstability data for each new location of a DM unit.\nStakeholders stated that the need for these data could be prohibitively burdensome\nfor applicants because DM units may be deployed to different locations ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"different locations within and\/\nor among host sites and may make smaller-than-traditional batch sizes. Although\ndrug product quality should be consistent across all DM units, some stakeholders\nopined that there may not be a need for comparability, validation, and stability data\nto support implementation at every new location because the risk to dru","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ause the risk to drug product\nquality may be mitigated if units are demonstrated to be cloned or like-for-like.\nHowever, some stakeholders noted that external factors beyond the DM unit, such\nas environment, utilities, personnel, and associated control procedures, might need\nto be controlled to ensure process performance and drug product quality at","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"g product quality at new\nmanufacturing locations.\nMost stakeholders agreed that the performance of DM units at a new location\nshould be evaluated to ensure consistent drug product quality, but many also\nagreed that the process to submit these data in an amendment or a supplement\nto an application could burden applicants making multiple or frequent ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ultiple or frequent location\nchanges. In addition, they acknowledged that FDA\u2019s assessment workload to\nreview such information could drastically increase. As a result, some stakeholders\nproposed alternative approaches wherein data to support new locations could be\ngenerated during product development and submitted and assessed in an original\napplic","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"n an original\napplication.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n9\nOne approach proposed by stakeholders centered on the use of existing\nassessment tools that have appropriate supporting data, such as comparability\nprotocols and\/or identified established conditions, to define criteria that must be\nmet following a ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" be\nmet following a move to a new location. Another stakeholder proposal advocated\nfor incorporating DM unit location moves into the process development studies\nto reduce the data needed to support postapproval moves and\/or establish an\noperational envelope (e.g., qualification\/validation and environmental parameters,\nutility requirements) within w","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"quirements) within which a DM unit would operate. Some explained\nthat there could continue to be a need to perform installation and operational\nqualification at each new manufacturing location. Stakeholders indicated that the\napproaches described above for demonstrating product comparability and process\nconsistency could be more challenging for CBE","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" challenging for CBER-regulated products, given the\ntypes of starting materials (e.g., autologous T cells) and their inherent variability.\nGenerally, stakeholders opined that the scope and nature of the data and\ninformation needed to support a new manufacturing location should be informed by\nthe capabilities of the DM unit, the potential risk of a ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"potential risk of a new location to drug product\nquality, and operator training.\nSome stakeholders stated that employing dedicated operators who move with a\nunit could reduce the risk to process and equipment performance and drug product\nquality. However, some noted that this type of approach might not be feasible for\nDM units that move frequently ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"hat move frequently and\/or over large geographical distances. In these\nscenarios, stakeholders noted that new personnel may need to be trained and\nqualified to operate DM units at each new location.\nG. Inspections\nThe October 2022 discussion paper acknowledged that FDA\u2019s establishment\nevaluation and inspection functions could face logistical and re","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ce logistical and resource\nchallenges due to: (1) the mobility and dispersion of DM units, (2) an increase in\nmanufacturing locations, (3) the intent to manufacture in or near nontraditional host\nsites, and (4) the intent to operate beyond one physical location (i.e., centralized\nPQS and host sites).\nThe most commonly proposed inspection model by s","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"nspection model by stakeholders was the\ninspection of a centralized PQS site, conducted on a risk-based frequency\nconsistent with FDA\u2019s current procedures for risk-based inspection schedules.\nStakeholders also encouraged the use of alternative tools (e.g., remote regulatory\nassessments) and advanced technology (e.g., augmented reality glasses) for ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"eality glasses) for host\nsite assessments.\nAnother suggested scenario was for FDA to conduct preapproval or prelicense\ninspections of host sites to support initial DM implementation, and then the\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n10\ncentralized PQS site would perform future host site evaluations that FDA could","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"tions that FDA could\nreview when inspecting the centralized PQS site. Stakeholder rationale for this\napproach was based on the premise that cloned or like-for-like DM units reduce\nrisks to drug product quality. Some explained that other factors, such as host site\nenvironmental and microbial controls, that are external to the DM unit at host sites\ns","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"unit at host sites\nshould continue to be subject to FDA evaluation, especially for nontraditional host\nsite environments.\nH. Considerations for Meeting Established Specifications\nIn general, stakeholders held the view that the intended uses and capabilities of\nself-contained DM units may impact the ability to use traditional tools to control\nqualit","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ls to control\nquality risks. For example, some posited that future host sites may not contain\ntraditional quality control laboratories, and operators may not be traditional\nmanufacturing operators (e.g., quality control analysts). Several stakeholders\nexplained that rapid, nontraditional approaches to release testing might be\nneeded for the viabili","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"eded for the viability of self-contained DM units. The most common approach\nthat stakeholders proposed was the use of process analytical technology (PAT)\nto enable real-time release testing. Although PAT has been developed for\nmanufacturing processes in traditional facilities, stakeholders noted that most of\nthese tools have not been miniaturized t","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" been miniaturized to the scale required for a self-contained\nDM unit. Some stakeholders also proposed approaches that do not rely on\nreal-time or end-product testing, including modeling and digital twins, parametric\nrelease, and conditional release. Stakeholders postulated that self-contained\nDM units could offer an advanced level of understanding","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"vel of understanding about processes and\nproducts, which, based on risks, might justify a combination of control approaches.\nSome stakeholders also supported that appropriate testing strategies may be\nproduct or technology specific, and risk assessments might determine whether\nsome uncertainties can only be monitored and controlled through end-prod","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"led through end-product\ntesting.\nA particular focus of stakeholders was quality testing for microbial and adventitious\nagents, which typically generate results within 7 to 14 days and could delay the\nadministration of product to patients. Stakeholders noted that rapid safety testing\nmethods for microbial and adventitious agents have seen limited im","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"have seen limited implementation.\nTherefore, some stakeholders proposed the potential combination of traditional and\nemerging methods, with other approaches, to ensure microbial and adventitious\nagent safety. Some noted that negative-to-date sterility results could permit rapid\nproduct release, while traditional testing results could provide confir","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"could provide confirmation or\nlead to initiation of risk mitigation measures. Some stakeholders noted that such\na process is analogous to the approach used for products with short half-lives\n(e.g., radiopharmaceuticals) for which sterility testing is performed after a dose\nhas been administered and protocols are established to address a failed ster","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ddress a failed sterility\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n11\ntest. Stakeholders also proposed that sterility testing may not be necessary for\nevery batch if a DM unit is a fully closed system that is appropriately validated to\nconsistently manufacture sterile products.\nImplementation of DM stability programs","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"M stability programs was an area of consideration for several\nstakeholders who noted that the design of stability programs might depend on a\ngiven technology and\/or product. An example given was drug products intended for\npatient administration within short time frames. Stakeholders seek guidance on the\nstability data (e.g., time-points, methods) n","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"e-points, methods) needed to support short expiry periods.\nBatch size was a stakeholder consideration for release and stability testing\nstrategies. Stakeholders noted that self-contained DM units might be designed\nto produce small batch sizes (even single doses) and noted that destructive\nend-product testing of such batches may not be feasible. Som","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"not be feasible. Some stakeholders\nproposed that samples produced from runs performed immediately before or\nafter a run producing material for patient administration (i.e., sub-batches) might\nbe used for release and stability testing. Some noted similarities between such a\nproposed approach and the existing approach used for PET drugs. Stakeholders","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" drugs. Stakeholders\nalso proposed that samples might be generated by additional process runs (i.e.,\nbatches) performed before and\/or after the run that produced the dose for patient\nadministration, provided that the samples used for release and stability testing are\nrepresentative and predictive of the administered batch.\nThe October 2022 discussi","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ctober 2022 discussion paper also posited that applicants who are not\npresent at host sites will face challenges with ensuring that any rejected\nmanufacturing components are quarantined, disposed of, and investigated.\nTo mitigate this issue, stakeholders proposed that a centralized PQS could provide\noversight and consistency in document management ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"document management and training, deviation\nidentification and handling, investigations, change controls, corrective actions and\npreventive actions (CAPA), and batch releases. Stakeholders proposed several\napproaches to control release of finished products, including using cloud-based\nand other electronic systems (e.g., artificial intelligence) at ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"al intelligence) at the centralized PQS\nsite to review batch records and data and\/or make automated decisions about\nbatch disposition (e.g., by using review by exception algorithms). Some noted\nit might be feasible for applicants to perform timely batch review and approval\nthrough the centralized PQS for all units at host sites (e.g., time zone-spe","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"(e.g., time zone-specific\nteams), while others ventured that sufficiently robust and appropriately validated\nautomated systems might be able to ensure proper batch decisions. Stakeholders\ndid not generally address procedures for handling rejected material at host sites\nor the processes by which self-contained DM units might physically detain and\/\no","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ically detain and\/\nor destroy nonconforming products to prevent use. Stakeholders noted that some\noperators may not be traditional manufacturing personnel and the extent of their\nquality responsibilities might be limited by their organization, though some noted\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n12\nthat robust ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"Plan\n12\nthat robust process controls might assist in ensuring that only conforming product\nis administered to patients.\nI. Other Regulated Products and Harmonization\n1. Other Regulated Products\nSome stakeholders highlighted similarities among drug products made in self-\ncontained DM units and PET drugs and other radiopharmaceuticals, noting that\nsu","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"cals, noting that\nsuch drug products might be made in enclosed, automated systems. Some\nstakeholders observed that PET drug products typically have short half-lives\nand, as a result, the final manufacturing step (e.g., radiolabeling) is performed\nin proximity to patient care. Some noted the unique considerations for ensuring\nquality of PET drugs in","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"lity of PET drugs in this environment and the specific regulations that cover\nthese products (i.e., part 212). Stakeholders suggested that some approaches\nused in the regulation of PET drugs could inform the regulation of self-contained\nDM units due to the potential parallels between the manufacturing of PET drugs\nand manufacturing in a self-contai","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ing in a self-contained DM unit. For example, some noted that\nprocesses used to train and qualify manufacturing unit operators and handle\nand investigate nonconformances at PET sites might inform approaches for self-\ncontained DM units. Additionally, some noted that digital tools (such as cloud-\nbased systems) are currently used to store manufactur","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" to store manufacturing records that a remote\nsite can access and use to ensure drug product quality. Several stakeholders\nspeculated that the testing and release strategies used in the manufacture of\nPET drugs and other radiopharmaceuticals could be examined for applicability\nto self-contained DM units.\nSome stakeholders cautioned that certain app","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ned that certain approaches for PET drug\nmanufacturing may not be appropriate for DM. One difference noted was that\nPET drugs are a narrow pharmaceutical class with distinct qualities that require\nmanufacturing in proximity to patients and for which the HCF is generally the\napplicant who operates a synthesizer and is responsible for quality oversig","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" for quality oversight\nand CGMP compliance. Some also noted that certain manufacturing process\ncan be more complex than radiolabeling and might result in higher lot-to-lot\nvariability relative to PET drugs.\nAlthough the October 2022 discussion paper excluded manufacturing units\nintended for drug compounding (i.e., drugs not adhering to the specific","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ring to the specification\nof an approved regulatory submission), stakeholders noted potential parallels\nbetween DM and drug compounding. The FRAME initiative continues to focus\non products that are the subject of approved applications (i.e., products that\nwould be marketed under a new drug application, an abbreviated new drug\napplication, or a biol","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"plication, or a biologics license application).\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n13\n2. International Harmonization\nStakeholders expressed a desire for international harmonization on\nterminologies and principles to facilitate the adoption of DM. Some suggested\nthat harmonization through global regulatory guide","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"bal regulatory guidelines (e.g., International\nCouncil for Harmonisation, pharmaceutical inspection convention\/\npharmaceutical inspection co-operation scheme (PIC\/S)) could mitigate\nuncertainty associated with deployment of manufacturing units to host sites\nacross broad geographical locations. Such an example provided was a\ncentral site in one regu","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ral site in one regulatory jurisdiction with host sites in other jurisdictions.\nStakeholders were clear that international collaboration among stakeholders and\nglobal regulators will be important, as these technologies continue to develop\nand deploy.\nIII. Action Plan Summary\n1. Seek and analyze input to ensure that FDA\u2019s understanding of\nDM technol","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"anding of\nDM technologies is thorough and analysis of the regulatory\nframework is science- and risk-based\nStakeholder Feedback:\nStakeholders developing DM technologies for drugs and biological products\nhave identified areas in which they seek additional regulatory clarity.\nFDA Action:\n\u2022\n\u2022\n\u2022\nPublish Distributed Manufacturing and Point-of-Care Manufa","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"Point-of-Care Manufacturing of Drugs\ndiscussion paper for public comment to share information with the public and\nrequest input on discussion questions related to the regulatory framework.\nSTATUS Completed with 60-day comment period that closed on December\n13, 2022\nIn partnership with PQRI, hold public workshop on the Regulatory Framework\nfor Distr","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" Framework\nfor Distributed and Point of Care Pharmaceutical Manufacturing: An\nOpportunity for DM\/POC Stakeholder Engagement to discuss stakeholder\ninput on these technologies.\nSTATUS Completed November 16, 2022\nEngage participants in the CDER Emerging Technology Program (ETP) and\nthe Center for Biologics and Research (CBER) Advanced Technologies Te","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"nced Technologies Team\nProgram (CATT) who are developing DM technologies and visit development\nsites.\nSTATUS Ongoing\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n14\n\u2022\nIncorporate input and feedback into priorities 2 and 3 below.\nSTATUS Ongoing\n2. Address risks to ensure that regulations and policy are\ncompatible with fut","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"\ncompatible with future DM technologies\nStakeholder Feedback:\nStakeholders seek assurance that regulations and policies are compatible with\nDM strategies for drugs and biological products.\nFDA Action:\n\u2022\nConduct a comprehensive analysis of regulatory requirements applicable to\nDM strategies for drugs and biological products.\nSTATUS Ongoing\n\u2022\nAssess ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"US Ongoing\n\u2022\nAssess the ability of FDA\u2019s IT systems to receive and store location\ninformation and inform inspections.\nSTATUS Ongoing\n3. Clarify expectations for stakeholders implementing DM\nStakeholder Feedback:\nStakeholders seek clarified regulatory expectations to facilitate the\nimplementation of DM for drugs and biological products.\nFDA Action:\n","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"oducts.\nFDA Action:\n\u2022\nDevelop guidance, as appropriate, to clarify areas of regulatory uncertainty,\nincluding the following proposed draft guidances: Considerations for Complying\nwith 21 CFR 211.110, Approaches to Meeting CGMP Requirements for\nDistributed Manufacturing, and Advanced Manufacturing Technologies\nDesignation Program Designated Technolo","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" Designated Technologies in Drug and Biological\nProducts.\n14\nSTATUS Ongoing\n\u2022\nEvaluate existing policy, incorporating stakeholder feedback, and develop\nguidance, as needed, to enable adoption of suitable DM technologies.\nSTATUS Ongoing\n14\nSee the document titled CDER Guidance Agenda, New & Revised Draft Guidance Documents Planned for Publication in","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"d for Publication in\nCalendar Year 2023 (July 2023), available at https:\/\/www.fda.gov\/media\/134778\/download.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n15\n4. Harmonize to ensure that global regulatory practice is clear to\nstakeholders implementing DM\nStakeholder Feedback:\nStakeholders seek international harmonization o","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"onal harmonization on the regulation of DM\ntechnologies to facilitate the adoption of DM for drugs and biological products.\nFDA Action:\n\u2022\nPublish internationally harmonized guidance for industry Q13 Continuous\nManufacturing of Drug Substances and Drug Products.15\nSTATUS Completed March 1, 2023\n\u2022\nCoordinate with international regulatory partners to ","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"ulatory partners to promote the global\nadoption of DM technologies.\nSTATUS Ongoing\n15\nFDA anticipates that many DM units, including self-contained DM units, will use continuous manufacturing.\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n16\nAppendix: Abbreviations\nFollowing is a list of abbreviations used in this paper:\nA","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"sed in this paper:\nAcronym Explanation\nAPI Active Pharmaceutical Ingredient\nCAPA Corrective Actions and Preventive Actions\nCATT CBER Advanced Technologies Team\nCBER Center for Biologics Evaluation and Research\nCDER Center for Drug Evaluation and Research\nCFR Code of Federal Regulations\nCGMP Current Good Manufacturing Practice\nDM Distributed Manufac","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" Distributed Manufacturing\nETP Emerging Technology Program\nFRAME Framework for Regulatory Advanced Manufacturing\nEvaluation\nGPS Global Positioning System\nHCF Health Care Facility\nHCT\/Ps Human Cellular and Tissue-Based Products\nICH International Council for Harmonisation\nIT Information Technology\nPAT Process Analytical Technology\nPET Positron Emissi","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":"\nPET Positron Emission Tomography\nPIC\/S Pharmaceutical Inspection Convention\/Pharmaceutical\nInspection Co-operation Scheme\nPOC Point-of-Care Manufacturing\nPQRI Product Quality Research Institute\nPQS Pharmaceutical Quality System\nSOP Standard Operating Procedures\nDistributed Manufacturing of Drugs: Stakeholder Feedback and Action Plan\n17\nU.S. Food a","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
{"chunk":" Plan\n17\nU.S. Food and Drug Administration\nwww.fda.gov\nOffice of Pharmaceutical Quality\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n10903 New Hampshire Avenue\nSilver Spring, Maryland 20993","book":"OPQ_Distributed_Manufacturing_Stakeholder Feedback_and_Action_Plan_233010"}
